- cafead Aug 30, 2024 at 11:42: AM
via A pooled analysis of data from four trials of Novo Nordisk’s obesity drug semaglutide found treatment reduced the risk of cardiovascular death or worsening heart failure by 31% compared to placebo.
article source
article source